Agent for eliminating senescent cells

Abstract

The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

1 - 11 . (canceled) 
     
     
         12 . A method for preventing a disease in which the disease state is expected to be improved by eliminating senescent cells, comprising administrating an effective amount of an SGLT2 inhibitor to a subject in need thereof. 
     
     
         13 . The method according to  claim 12 , wherein the SGLT 2 inhibitor is at least one selected from the group consisting of low molecular weight compounds, SGLT2 expression inhibitors, and SGLT2-specific binding substances. 
     
     
         14 . The method according to  claim 12 , wherein the SGLT 2 inhibitor is at least one selected from the group consisting of canagliflozin, empagliflozin, ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, ertugliflozin, sotagliflozin, and pharmaceutically acceptable salts thereof. 
     
     
         15 . The method according to  claim 12 , wherein the SGLT2 inhibitor is administered as a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier. 
     
     
         16 . The method according to  claim 12 , wherein the disease state is a senescence-related disease. 
     
     
         17 . The method according to  claim 16 , wherein the senescence-related disease is at least one selected from the group consisting of pulmonary fibrosis, emphysema, skeletal muscle atrophy (sarcopenia), osteoarthritis, dementia, frailty, cancer, glaucoma, age-related macular degeneration, presbyopia, age-related alopecia, age-related hearing loss, pain associated with aging, lumbar pain, joint pain, asteatotic eczema, cutaneous pruritus, fatty liver, nonalcoholic steatohepatitis (NASH), liver cirrhosis, osteoporosis, osteoarthropathy, Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and Rothmund-Thomson syndrome. 
     
     
         18 . The method according to  claim 17 , wherein the senescence-related disease is at least one selected from the group consisting of Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and Rothmund-Thomson syndrome. 
     
     
         19 . The method according to  claim 17 , wherein the senescence-related disease is at least one selected from the group consisting of skeletal muscle atrophy (sarcopenia), dementia, and frailty. 
     
     
         20 . The method according to  claim 12 , wherein the method selectively reduces or eliminates senescent cells. 
     
     
         21 . The method according to  claim 20 , wherein the SGLT2 inhibitor is canagliflozin. 
     
     
         22 . The method according to  claim 12 , wherein the method suppresses an increase of expression of p53, p16 and/or p21.